Literature DB >> 17697895

Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression.

Yuliya Pylayeva1, Wenjun Guo, Filippo G Giancotti.   

Abstract

Cancer progression-the evolution of malignant tumors towards metastatic dissemination-is a complex, multistep process orchestrated by neoplastic cells but aided by elements of the tumor microenvironment such as macrophages, activated fibroblasts, and endothelial cells. During tumor progression, cancer cells acquire a number of traits, such as the ability to undergo unrestrained proliferation, to resist pro-apoptotic insults, and to invade through tissue boundaries. Genetic and epigenetic changes conspire to drive the emergence of these traits against the backdrop of host selection. It is becoming increasingly clear that certain integrins and integrin-signaling components amplify oncogenic signaling to promote tumor progression. Mouse models of cancer provide useful, if not necessary, experimental systems to study tumor initiation and progression in vivo and to test novel therapeutic approaches. We have utilized mouse models of mammary tumorigenesis to examine the role of integrin alpha6beta4 signaling in tumor progression in vivo. In this chapter, we describe a collection of cell biological and genetic methods that may aid in characterizing the roles of integrin signals in mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697895     DOI: 10.1016/S0076-6879(07)26019-7

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  3 in total

1.  M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.

Authors:  Yuxin Shu; Menghao Qin; Yue Song; Qing Tang; Yahong Huang; Pingping Shen; Yan Lu
Journal:  Immunology       Date:  2020-04-29       Impact factor: 7.397

2.  Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Authors:  Wei Li; Liru You; Jonathan Cooper; Gaia Schiavon; Angela Pepe-Caprio; Lu Zhou; Ryohei Ishii; Marco Giovannini; C Oliver Hanemann; Stephen B Long; Hediye Erdjument-Bromage; Pengbo Zhou; Paul Tempst; Filippo G Giancotti
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

3.  Integrin-blocking antibodies delay keratinocyte re-epithelialization in a human three-dimensional wound healing model.

Authors:  Christophe Egles; Heather A Huet; Furkan Dogan; Sam Cho; Shumin Dong; Avi Smith; Elana B Knight; Karen R McLachlan; Jonathan A Garlick
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.